Immune Pharmaceuticals Inc.
IMNP
IMNP was delisted on the 25th of July, 2018.
17 hedge funds and large institutions have $183K invested in Immune Pharmaceuticals Inc. in 2018 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 3 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
13% more funds holding
Funds holding: 15 → 17 (+2)
49% less capital invested
Capital invested by funds: $360K → $183K (-$177K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
+$46.1K |
| 2 |
EDRH
Edmond de Rothschild Holding
Chambesy,
Switzerland
|
+$41.1K |
| 3 |
IP
Intellectus Partners
San Francisco,
California
|
+$14.8K |
| 4 |
Goldman Sachs
New York
|
+$13.5K |
| 5 |
Bank of New York Mellon
New York
|
+$6.98K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$133K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$34.2K |
| 3 |
VF
Virtu Financial
New York
|
-$14K |
| 4 |
JP Morgan Chase
New York
|
-$7K |
IMNP Hedge Fund Activity: Q1 2018 in Review
17 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Immune Pharmaceuticals Inc. (IMNP) for Q1 2018, worth a combined $183K — down 49% from $360K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new IMNP positions and 3 closed out — a net gain of 2 holders — while 5 added to existing stakes and 2 trimmed.
The largest buyer was Barclays, opening a new position worth an estimated $46.1K. The largest seller was Vanguard Group, cutting an estimated $133K.
- 17 institutional investors held Immune Pharmaceuticals Inc. (IMNP) as of Q1 2018, up from 15 in Q4 2017.
- Funds reported $183K of Immune Pharmaceuticals Inc. stock for Q1 2018, down 49% quarter-over-quarter.
- 5 funds opened new Immune Pharmaceuticals Inc. positions in Q1 2018 and 3 closed out, a net change of +2 holders.
- The largest Immune Pharmaceuticals Inc. buyer in Q1 2018 was Barclays, an estimated $46.1K added.
- The largest Immune Pharmaceuticals Inc. seller in Q1 2018 was Vanguard Group, an estimated $133K sold.
Based on aggregated 13F filings for Q1 2018.